Evidence of a stabilisation in business activity with the early signs of a recovery emerged in the recent the year-end trading update (30.04.24) and in management commentary at an investor presentation (16.05.24) at Fusion Antibodies plc. The update suggests revenue of £599k was recorded in the H2 FY24, in line with expectations set at the time of the last fundraising. This represents a ~10% rise over H1’s £541k, although this is still well down on the comparative period. However, revenue in the ....
![working](/images/WorkingLarge.gif)
20 May 2024
Allenby Capital: Fusion Antibodies - Update
![](/images/orange-lock.png)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Allenby Capital: Fusion Antibodies - Update
Fusion Antibodies Plc (FAB:LON) | 3.4 0 0.0% | Mkt Cap: 3.29m
- Published:
20 May 2024 -
Author:
Robin Davison | John Savin -
Pages:
5 -
Evidence of a stabilisation in business activity with the early signs of a recovery emerged in the recent the year-end trading update (30.04.24) and in management commentary at an investor presentation (16.05.24) at Fusion Antibodies plc. The update suggests revenue of £599k was recorded in the H2 FY24, in line with expectations set at the time of the last fundraising. This represents a ~10% rise over H1’s £541k, although this is still well down on the comparative period. However, revenue in the ....